Pinned Tweet
Our latest paper is now online @MDJ_Journal! Following our previous GWAS finding, here we show biomarker evidence of LRRK2 being relevant to the progression of PSP - another step closer to a LRRK2-targeting trial for PSP patients. Funding from @CurePSP. movementdisorders.onlinelibr…
Ed Jabbari retweeted
Replying to @KristopheDiaz
@KristopheDiaz @Divyani_Garg @JackyGanguly @mehtasahilpgi @dr_heli @drsoaham @DrMiteshC @rukminimridula @atabisneuro @AdreeshMukhrj @Freewill_Hrishi – at Songpa-gu, Republic of Korea
New genetic clues to PSP from India!
At the IPMDS #MDSCongress? Visit our late-breaking abstract, LBA 3, to explore the PAIR-PSP findings and connect with our team.
We are proud to share the first South Asian genome-wide association study (GWAS) of progressive supranuclear palsy (PSP)—bringing an underrepresented population into the search for answers to this devastating disease.
🔬 From discovery to replication
Our discovery study included 800 genotyped PSP cases, with 784 analyzed against 3,184 South Asian controls. Six reported loci reached genome-wide significance.
We then evaluated the findings in a separate cohort of 200 PSP cases and 200 controls. Two loci showed replication evidence:
• CD2AP, chromosome 6
Discovery p=9.9×10⁻¹⁰ | Replication p=0.0071
• PPARGC1A, chromosome 4
Discovery p=3.1×10⁻⁹ | Replication p=0.0033
These findings strengthen the evidence for these associations and support further investigation into tau-related processes, cellular transport and mitochondrial biology in PSP.
🌏 Why ancestry matters
The prominent MAPT association reported in European PSP studies was not detected in our Indian cohort. This does not mean MAPT is absent or irrelevant in Indians. Differences in allele frequencies, genetic architecture and statistical power need careful consideration.
It raises an important question: what might we learn when more populations are represented in genetic research?
For me, PAIR-PSP demonstrates the value of building deeply characterized cohorts in India and connecting them with global scientific collaboration. Discovery followed by replication is an important milestone; understanding how these findings contribute to disease biology is the next step.
🤝 The people behind the findings
My sincere thanks to the patients and families who participated, our collaborating clinicians across India, and colleagues at the Parkinson’s Research Alliance of India (PRAI), @MedGenomeLabs and the Global Parkinson’s Genetics Program (GP2 @ASAP_Research ).
This is a shared achievement, built on trust, participation and sustained teamwork.
Please visit LBA 3—we would welcome your questions, perspectives and opportunities to collaborate.
#PSP #GWAS #PAIRPSP #Neurogenetics @movedisorder @curepsp
Ed Jabbari retweeted
Listen to this salutary story that has so many lessons.
if a normal DAT scan doesn’t absolutely exclude early Parkinson’s disease why do it in the first place. Second if there is no sequence effect on 20s of tapping - hold your horses @Ed_Jabbari
share.google/NiRalvsIstjvUDi…
Ed Jabbari retweeted
Excited to share that my PhD work on STX6 and tau is now published in Acta Neuropathologica (@SpringerNature)! Huge thanks to everyone at the @MRC_Prion Unit for their support—especially my supervisor @smead2 . You can read it here: rdcu.be/feQoF
Incredibly sad news. Byron was a giant in his field and will be sorely missed. His support and willingness to make time for others was limitless, and I’d like to share one particular story about how he touched my life 🧵
None of that would have been possible without Byron. Just last week, he continued to support the set up of my lab by sharing protocols and material. I have no doubt that he will live on in the work that we do, and there are more joint papers in the pipeline.
Ed Jabbari retweeted
New review from @Davidgcoughlin & #Parkinsons Study Group colleagues explores the current utility & limitations of CSF α-synuclein seed amplification assays & skin immunofluorescence as diagnostic tools, the need for formal guidelines, & knowledge gaps
neurology.org/doi/10.1212/WN…
Ed Jabbari retweeted
The sequel to #NeurologicalBirdsong is out for Christmas. Press the button and it will be with you tomorrow.
An ideal gift for all life scientists
@MirabeauPress @ACNRjournal @PracticalNeurol @UCLIoN
Murmuration amzn.eu/d/hmkYXAo
A reminder that there is no such thing as the perfect biomarker. Lead with your clinical nose + in this case the rapid progression should prompt testing for alternative pathologies. Cortical ribboning has high sensitivity in CJD so not to miss, and send RT-QuIC for confirmation.
A humbling case (evaluated at 4 major university hospitals): final diagnosis made only at autopsy.
link.springer.com/article/10…
Takeaways:
• Always consider prion disease in rapidly progressive neurologic disorders
• α-synuclein skin biopsy isn’t always reliable
@ClinAutonRes
Ed Jabbari retweeted
Just out today. Please share widely to improve recognition and awareness of non motor symptoms in dystonia. @DystoniaUK @SankethRampes
mdpi.com/2076-3425/15/12/129…
Very pleased to share our latest work (under review): a collaborative effort between us, @mrcppu + @biogen, funded by @CurePSP. In this study we have comprehensively assessed blood, CSF + urine based biomarkers of LRRK2 + lysosomal dysfunction in PSP (1/7)
medrxiv.org/content/10.1101/…
LRRK2 therapeutics are currently being trialled in PD as a disease modifying therapy. We believe that our findings will stimulate a lot of interest to extend this approach to PSP patients, with @ArvinasInc recently announcing their plans here: ir.arvinas.com/news-releases… (6/7)
As always, a huge thank you to all of our patients and collaborators who make the work possible!
@UCLIoN @MDC_IoN_UCL @CurePSP @PSPAssociation @AngelaCacace3 @KristopheDiaz @ScienceofPD @movedisorder (7/7)


















